Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Institut Curie
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Global Survival Data collection of the efficacity of PD-1 inhibitors
Study Overview
Brief Summary
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
Detailed Description
The aim of the research is to study the activity of PD-1 inhibitors in patients with metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have already received the authorities approvals. The data collected will be crucial for the understanding of the mechanism of PD-1 inhibitors and also for the futures studies.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with metastatic uveal melanoma
- •Patients who received at least once injection of Nivolumab or Pembrolizumab in the case of the disease's treatment
Exclusion Criteria
- •Antecedent of another evolutionary tumor pathology
Outcomes
Primary Outcomes
Global Survival Data collection of the efficacity of PD-1 inhibitors
Time Frame: December 2019
Description of Global Survival
Stability Data collection of the efficacity of PD-1 inhibitors
Time Frame: December 2019
Description of Stability at 6 months
Response rate Data collection of the efficacity of PD-1 inhibitors
Time Frame: December 2019
Description of Response rate
Objective response Data collection of the efficacity of PD-1 inhibitors
Time Frame: December 2019
Description of Objective response
Progression Free Survival Data collection of the efficacity of PD-1 inhibitors
Time Frame: December 2019
Description of PFS (Progression Free Survival)
Secondary Outcomes
- Exploration of PD-1 inhibitors biomarkers(December 2019)